Giacomelli Chiara, Daniele Simona, Romei Chiara, Tavanti Laura, Neri Tommaso, Piano Ilaria, Celi Alessandro, Martini Claudia, Trincavelli Maria L
Department of Pharmacy, University of Pisa, Pisa, Italy.
Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Front Pharmacol. 2018 Jan 31;9:54. doi: 10.3389/fphar.2018.00054. eCollection 2018.
The epithelial-mesenchymal transition (EMT) is a complex process in which cell phenotype switches from the epithelial to mesenchymal one. The deregulations of this process have been related with the occurrence of different diseases such as lung cancer and fibrosis. In the last decade, several efforts have been devoted in understanding the mechanisms that trigger and sustain this transition process. Adenosine is a purinergic signaling molecule that has been involved in the onset and progression of chronic lung diseases and cancer through the A adenosine receptor subtype activation, too. However, the relationship between AAR and EMT has not been investigated, yet. Herein, the AAR characterization was carried out in human epithelial lung cells. Moreover, the effects of receptor activation on EMT were investigated in the absence and presence of transforming growth factor-beta (TGF-β1), which has been known to promote the transition. The AAR activation alone decreased and increased the expression of epithelial markers (E-cadherin) and the mesenchymal one (Vimentin, N-cadherin), respectively, nevertheless a complete EMT was not observed. Surprisingly, the receptor activation counteracted the EMT induced by TGF-β1. Several intracellular pathways regulate the EMT: high levels of cAMP and ERK1/2 phosphorylation has been demonstrated to counteract and promote the transition, respectively. The AAR stimulation was able to modulated these two pathways, cAMP/PKA and MAPK/ERK, shifting the fine balance toward activation or inhibition of EMT. In fact, using a selective PKA inhibitor, which blocks the cAMP pathway, the AAR-mediated EMT promotion were exacerbated, and conversely the selective inhibition of MAPK/ERK counteracted the receptor-induced transition. These results highlighted the AAR as one of the receptors involved in the modulation of EMT process. Nevertheless, its activation is not enough to trigger a complete transition, its ability to affect different intracellular pathways could represent a mechanism at the basis of EMT maintenance/inhibition based on the extracellular microenvironment. Despite further investigations are needed, herein for the first time the AAR has been related to the EMT process, and therefore to the different EMT-related pathologies.
上皮-间质转化(EMT)是一个复杂的过程,在此过程中细胞表型从上皮型转变为间质型。该过程的失调与肺癌和纤维化等多种疾病的发生有关。在过去十年中,人们致力于理解触发和维持这一转化过程的机制。腺苷是一种嘌呤能信号分子,也通过激活A腺苷受体亚型参与了慢性肺部疾病和癌症的发生与发展。然而,A受体与EMT之间的关系尚未得到研究。在此,对人肺上皮细胞进行了A受体的特性研究。此外,在存在和不存在已知可促进转化的转化生长因子-β1(TGF-β1)的情况下,研究了受体激活对EMT的影响。单独激活A受体分别降低和增加了上皮标志物(E-钙黏蛋白)和间质标志物(波形蛋白、N-钙黏蛋白)的表达,但未观察到完全的EMT。令人惊讶的是,受体激活抵消了TGF-β1诱导的EMT。几种细胞内途径调节EMT:已证明高水平的cAMP和ERK1/2磷酸化分别抵消和促进转化。A受体刺激能够调节这两条途径,即cAMP/PKA和MAPK/ERK,使微妙的平衡向激活或抑制EMT方向转变。事实上,使用阻断cAMP途径的选择性PKA抑制剂会加剧A受体介导的EMT促进作用,相反,选择性抑制MAPK/ERK则会抵消受体诱导的转化。这些结果突出了A受体是参与调节EMT过程的受体之一。然而,其激活不足以触发完全的转化,其影响不同细胞内途径的能力可能代表了一种基于细胞外微环境的EMT维持/抑制机制。尽管还需要进一步研究,但在此首次将A受体与EMT过程联系起来,因此也与不同的EMT相关病理联系起来。